Developer docs
API playgroundTry for free, no card

Search company profiles

Novonesis

Full company profile

uuid00022zi

Namestring
Novonesis
Legal namestring
Novozymes A/S, part of Novonesis Group
Websiteurl
novonesis.com
Company typeenum
Public
Founded yearint
2024
Descriptiontext

Novonesis is a publicly traded biosolutions company headquartered in Hørsholm, Denmark (with principal operating presence at Lyngby), formed in January 2024 through the combination of Novozymes (spun off from Novo Nordisk in 2000) and Chr. Hansen (founded 1874). The company develops and sells enzyme, microbial, probiotic, culture, yeast, and functional protein biosolutions derived from biological sources for industrial and consumer applications. Its products span bioenergy (ethanol, biodiesel, biogas, renewable diesel, carbon capture), food and beverages (dairy, baking, beverages, meat, plant-based foods), household care (laundry and dishwash), human health (probiotics, early life nutrition, precision proteins), animal and plant solutions, and industrial bioprocessing (starch, oils & fats, leather, pulp & paper, sustainable plastics, textile, water treatment), with flagship trademarked platforms including Eversa, FlexFit, Cellic, Cellerity, Quara, BB-12, Pylopass, Urex, Alflorex, and DVS.

The technology stack rests on proprietary strain libraries and fermentation/biocatalysis platforms built over more than 100 years, paired with application engineering, regulatory dossier infrastructure for health claims, and approximately 25+ manufacturing facilities and R&D centers across the Americas, EMEA, and Asia Pacific. Strategic product franchises include proprietary probiotic strains documented over decades, enzymatic biodiesel processing (Eversa Advance, FlexFit), cellulosic ethanol enzyme blends (Cellic) and yeast (Cellerity), renewable diesel pretreatment (Quara LowP/Supreme), and emerging enzymatic carbon capture via carbonic anhydrase.

Novonesis generates revenue primarily through direct B2B product sales of biosolutions to enterprise customers across Food & Beverages, Human Health, and Planetary Health divisions, complemented by channel partnerships (notably Rovensa Next for US agricultural biosolutions) and regional distributors in emerging markets. The company serves more than 30 industries with 11,000+ employees and reports serving 200+ oils-and-fats plants globally; its biosolutions are embedded in 50%+ of all bread, yogurt, and cheese produced globally and reach 2 billion people daily through food applications. Leadership is anchored by a globally experienced executive team including CEO Ester Baiget (ex-Dow) and CFO Rainer Lehmann (ex-Sartorius), with Novo Holdings A/S (Novo Nordisk Foundation) controlling 25.50% of shares and 63.35% of voting rights via dual-class share structure. Q1 2026 results showed 7% organic sales growth and 37.8% adjusted EBITDA margin, supporting a 2026 revenue forecast of approximately $5.25 billion and a 2030 roadmap targeting 6-9% organic sales CAGR and ~39% adjusted EBITDA margin against a stated EUR 60 billion biosolutions TAM.

Short descriptiontext

Novonesis is a publicly traded Danish biosolutions company developing enzymes, microbes, probiotics, cultures, yeasts, and functional proteins for food and beverages, human health, household care, animal nutrition, bioenergy, and industrial bioprocessing customers across more than 30 industries globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
5,001–10,000
akta.pro rankint
HeadquartersLyngby, Denmark
HQ citystring
Lyngby
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices26 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
industrial enzyme solutions, microbial biosolutions, probiotic cultures, bioenergy enzymes, food fermentation ingredients
Industry1 code
1Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling)
CodeHLAAAJAFPrimaryYes
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Medicinal Chemicals & Botanical Products2833
  • Food And Kindred Products2000
Product category
Industrial Biotechnology and Biosolutions
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Biosolutions Product Sales
TypeOthers
Description

Novonesis generates revenue primarily through the sale of biosolutions including enzymes, microbes, probiotics, cultures, yeasts, and functional proteins to customers across 30+ industries. Revenue is generated from product sales across Food & Beverages, Human Health, and Planetary Health divisions.

novonesis.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 10 records shown
1Eversa
Description

Enzymatic biodiesel processing solutions including Eversa Advance and Eversa Transform 2.0 biocatalysts

novonesis.com
+9 more records
Core offering1 text field

Novonesis develops, manufactures, and sells biosolutions — enzymes, microbes, probiotics, cultures, yeasts, and functional proteins — to industrial customers across more than 30 industries. Its products are organized into two divisions: Planetary Health Biosolutions (food & beverages, bioenergy, household care, animal & plant, industrial bioprocessing) and Human Health Biosolutions (dietary supplements, early life nutrition, precision proteins). Revenue is generated primarily through direct product sales to enterprise customers supplemented by channel partner distribution.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 7% organic sales growth in Q1 2026
+7 more records
Product overview1 text field

Novonesis is a world-leading biosolutions company offering a broad portfolio of enzyme, microbial, probiotic, culture, and functional protein products organized around two divisions: Planetary Health Biosolutions and Human Health Biosolutions. The company serves more than 30 industries including bioenergy (ethanol, biodiesel, biogas, biomass, renewable diesel, carbon capture), food and beverages (dairy, baking, beverages, meat, plant-based foods, functional foods), household care (laundry, dishwashing, home cleaning, industrial cleaning), human health (dietary supplements, early life nutrition, precision proteins, probiotics), and industrial bioprocessing (starch, oils & fats, leather, pulp & paper, sustainable plastics, textile, water treatment). The portfolio was significantly expanded through the January 2024 merger of Novozymes and Chr. Hansen, and further through the 2025 acquisition of dsm-firmenich's Feed Enzyme Alliance. Key product brands include Eversa® (biodiesel biocatalysts), FlexFit® (enzymatic process), Cellic® (biomass enzymes), Cellerity® (yeast technology), Quara® (oil processing), BB-12™ and Alflorex® (probiotics), Pylopass™ and Urex™ (microbiome strains), DVS® (fermentation technology), and the Protective Cultures platform for bioprotection. The company operates globally through approximately 100 subsidiaries and a direct commercial presence across all major regions.

Product and service26 records
1Eversa® Advance
CategoryBiodiesel enzymes
Description

An enzymatic biocatalyst for biodiesel processing that enables conversion of used cooking oil and tallow into biodiesel, delivering up to 3% additional yield versus acid esterification and glycerolysis, and up to 45% reduction in operating costs. Targeted at biodiesel producers seeking feedstock flexibility.

2Eversa® Transform 2.0
CategoryBiodiesel enzymes
Description

An enzyme biocatalyst that simultaneously catalyzes transesterification of glycerides and esterification of free fatty acids (FFA), enabling processing of low-quality feedstocks with high FFA content in biodiesel production. For biodiesel producers working with challenging feedstocks.

3FlexFit® Biodiesel Process
CategoryBiodiesel process technology
Description

An enzymatic transesterification process for biodiesel production providing feedstock flexibility, reduced capital expenditure by avoiding expensive high-temperature equipment, and lower operating expenses through operation at 35–40°C. For biodiesel producers seeking capex and opex reductions.

4Cellic® CTec3 HS
CategoryCellulosic ethanol enzymes
Description

A multi-enzyme blend for cellulosic ethanol production offering low cost-in-use and process flexibility, suited to simultaneous saccharification and fermentation (SSF) processes. For cellulosic ethanol producers converting agricultural residues.

5Cellerity® 1.0
CategoryCellulosic ethanol yeast technology
Description

A yeast technology for cellulosic ethanol fermentation offering broad robustness, fast ethanol production, flexibility in nitrogen sources, lower CAPEX, and rapid xylose conversion. For second-generation biofuel producers.

6Carbonic Anhydrase Enzymatic Carbon Capture
CategoryCarbon capture enzymes
Description

An enzyme for post-combustion carbon capture that converts CO₂ molecules into carbonate, enabling more efficient and affordable capture compared to traditional chemical methods and requiring only 80°C thermal energy versus 120°C for conventional processes. For carbon capture, utilization, and storage (CCUS) operators.

7Quara® LowP
CategoryRenewable diesel enzymes
Description

An enzymatic pretreatment solution for HVO/HEFA renewable diesel feedstocks that helps crushing and refining plants meet quality specifications with maximum yield and minimum by-products, providing feedstock flexibility and reducing waste. For renewable diesel producers.

8Quara® Supreme
CategoryVegetable oil processing enzymes
Description

A thermostable enzymatic water-degumming solution that improves crude vegetable oil yield and operational flexibility for soybean, rapeseed, and canola refining, reducing yield losses without increasing free fatty acids. For edible oil refiners.

9HMO (Human Milk Oligosaccharides)
CategoryHuman milk oligosaccharides
Description

Ingredients for early life nutrition that help infant formula provide nourishment closer to nature's intent. Production supported by the acquired Thailand facility from Meihua. For infant formula and early-life nutrition manufacturers.

10Precision Proteins
CategoryFunctional proteins
Description

Tailored protein solutions to meet exact nutritional needs throughout consumers' different stages of life, part of the human health biosolutions portfolio. For human nutrition and dietary supplement manufacturers.

11Microbial Solutions (Plant)
CategoryAgricultural microbial solutions
Description

Naturally occurring microbes and enzymes for agriculture that help farmers improve plant health and increase crop yield, supporting sustainable farming through biological interventions. For row crop, specialty crop, and forage producers, distributed in the US via Rovensa Next from the 2027 growing season.

12Microbial Solutions (Animal)
CategoryAnimal nutrition biosolutions
Description

Science-based probiotics, microbes, and enzymes for animal health that work in synergy with agricultural strategies to drive consistent results in livestock production. For animal feed manufacturers and livestock producers, expanded through the dsm-firmenich Feed Enzyme Alliance acquisition completed in February 2025.

13Laundry Enzymes
CategoryHousehold care enzymes
Description

Enzyme solutions for laundry applications that deliver superior cleaning at competitive price points, enabling biodegradable and renewable formulations. For detergent and household-care manufacturers.

14Dishwashing Enzymes
CategoryHousehold care enzymes
Description

Enzyme solutions for dishwashing that boost performance from scrubbing power to quick cleaning, supporting eco-friendly, biodegradable, and renewable formulations. For automatic dishwashing detergent manufacturers.

15DVS® Technology (Direct Vat Set)
CategoryDairy fermentation technology
Description

A fermentation technology introduced in 1978 that transformed fermentation into a modern biotechnology platform, enabling consistent, high-performance cultures for dairy and food fermentation. For dairy manufacturers producing cheese, yogurt, and other fermented dairy products.

16Protective Cultures (Bioprotection)
CategoryFood bioprotection cultures
Description

Food safety biosolutions launched in 2012 that slow spoilage yeasts and molds, keeping dairy products fresh for longer and reducing food waste. For dairy and food manufacturers seeking shelf-life extension.

17Starch Enzymes
CategoryIndustrial starch processing enzymes
Description

Enzymes central to efficient starch processing, from corn separation to natural sweeteners, part of Novonesis's industrial bioprocessing portfolio. For starch processors and sweetener manufacturers.

18Oils & Fats Enzymes
CategoryIndustrial oils and fats enzymes
Description

Enzymatic processing solutions for oils and fats that reduce chemical use, enable switching to low-cost feedstocks, and improve profitability for edible oil producers. Used by 200+ oils and fats processing plants globally.

19Leather Enzymes
CategoryLeather processing enzymes
Description

Biosolutions for leather processing that serve as alternatives to chemicals, making leather processing gentler and easier while significantly improving quality. For tanneries and leather goods manufacturers.

20Pulp & Paper Enzymes
CategoryPulp and paper enzymes
Description

Biosolutions for pulp and paper mills that help meet growing demand while achieving sustainability goals, reducing environmental impact of paper production. For pulp and paper manufacturers.

21Sustainable Plastics Enzymes
CategoryPlastics enzymes
Description

Enzymatic biosolutions that reduce the environmental impact of plastics and increase recyclability, addressing plastic waste through biological degradation. For plastics manufacturers and recyclers.

22Textile Enzymes
CategoryTextile processing enzymes
Description

Biodegradable, environmentally friendly enzymes for textiles that support mills and laundries in the circular fashion movement. For textile mills and garment manufacturers.

23Water Treatment Enzymes
CategoryWater treatment enzymes
Description

Enzyme solutions that improve water purification and process water quality while reducing chemical use, supporting efficient water recycling and lower environmental footprint. For water treatment and industrial process water operators.

24Biogas Enzymes
CategoryBiogas enzymes
Description

Tailor-made enzyme solutions for biogas production from agricultural residues, food production waste, wastewater, and sewage, delivering higher biogas yields, reduced operational costs, and prevention of hard crust formation in digesters. For biogas plant operators.

25BB-12™ Probiotic Strain
CategoryProbiotic strains
Description

One of the world's most researched Bifidobacterium strains, supporting immune function, digestive health, and overall wellbeing across all ages, introduced in 1984. For dietary supplement, dairy, and infant nutrition manufacturers seeking clinically documented probiotic strains.

26Feed Enzyme Alliance (Animal Nutrition)
CategoryAnimal feed enzymes
Description

Animal feed enzyme business acquired from dsm-firmenich for approximately EUR 1.5 billion in February 2025, combining enzyme, microbe, and probiotic innovation for animal nutrition with global sales and distribution. For animal feed manufacturers and livestock producers.

Scale indicator28 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-19
Description

MoU signed at Embassy of Denmark in Hanoi to jointly boost domestic bioethanol production supporting Vietnam's E10 fuel rollout. Partnership combines Novonesis enzyme and yeast technology for corn and cassava-based ethanol with Nhà Xanh production infrastructure to address Vietnam's estimated 75,000 cubic meters monthly ethanol supply shortfall worth approximately USD 1 billion annually in imports.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-11
Description

Distribution agreement under which Rovensa Next commercializes select Novonesis agricultural biosolutions in the United States beginning with 2027 growing season. Rovensa Next assumes direct commercial responsibility for products covering soybeans, corn, pulses, peanuts, and fruit/vegetable crops, expanding its full crop-cycle portfolio from planting to post-harvest.

3UndoAge
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-06-09
Description

MoU signed in Beijing forming strategic partnership to collaborate in China's probiotics and microbiome health market, focusing on stomach health and women's microbiome health segments. Collaboration leverages Novonesis proprietary probiotic strains (Pylopass™ and Urex™) and UndoAge consumer market expertise to develop science-backed products under 'Healthy China' strategy.

aijourn.com
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-05-21
Description

Partnership earned 2026 PRSA Silver Anvil Award for Manufacturing Day 2025 campaign designed to inspire students about biomanufacturing careers. Novonesis was national flagship host site welcoming hundreds of students to facilities in North Carolina, Virginia, and Wisconsin.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-23
Description

Next phase of nine-year strategic partnership formalized with new agreement at leadership meeting in Copenhagen. Partnership focused on microbiome science and consumer health, expanding scientific collaboration and market reach for flagship product Alflorex®, now available in over 15 countries. Agreement expected to accelerate growth through deeper scientific collaboration.

Strategic tierInnovationTypeTechnology or IntegrationAnnounced on2025-11-19
Description

Danish quantum computing software company launched Qrunch platform for chemical and biological engineering industries. Novonesis already using technology to improve enzyme products and model larger molecular systems for pharmaceutical applications. Platform enables domain scientists to build quantum algorithms without quantum expertise.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-11-18
Description

Partnership to develop enzymatic fat-splitting process replacing traditional thermal methods, reducing energy and water consumption in oleochemical production. New process operates at lower temperatures and pressures, offering significant cost savings, flexibility, and sustainability benefits.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Partnership to deliver enzyme-based, cost-effective carbon capture solution. SAIPEM leverages expertise as leading EPC provider with advanced CCUS technology and proven track record in plant construction. Novonesis supports with robust global enzyme supply chain, R&D capabilities, and world-class enzyme quality for large-scale applications.

Strategic tierInnovationTypeStrategic or Co-development Partner
Description

Collaboration on CO₂ to protein sustainable food innovation projects. Partnership leverages academic research capabilities with Novonesis industrial biotech expertise.

Strategic tierAcquisitionTypeOthers
Description

Novonesis acquired production facility in Rayong, Thailand from Meihua for approximately USD 50 million, expanding footprint in Southeast Asia and strengthening fermentation capabilities. Facility expected to be commercially operational in 2027 and will support HMO production.

Strategic tierWorkforce DevelopmentTypeOthers
Description

Novonesis supported development of NC State's agricultural formulations certificate program designed to prepare workforce-ready scientists for developing pesticides, fertilizers, growth regulators and biological products. Faculty from multiple departments collaborating on initiative.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
1AB Enzymes (ABF Ingredients)
TypeDirect peer
Description

Germany-based industrial enzyme specialist focused on food, beverage, and industrial applications; competes in baking, starch, and beverage enzyme categories.

TypeDirect peer
Description

IFF's Health & Biosciences division (including the legacy DuPont N&B enzyme and cultures business) directly competes with Novonesis in food enzymes, cultures, probiotics, and bioprocessing ingredients, serving overlapping F&B customers globally.

TypeDirect peer
Description

Dutch-Swiss nutrition and biosciences major; Novonesis acquired its Feed Enzymes Alliance in Feb 2025 but DSM-Firmenich remains a peer across animal nutrition, human nutrition, and personal care biosolutions.

TypeDirect peer
Description

French global yeast and fermentation leader with overlapping capabilities in baking, brewing, bioethanol, and human nutrition probiotics; competes with Novonesis's DVS® cultures, yeast, and Cellerity® technologies.

TypeDirect peer
Description

Canadian privately held yeast and bacteria producer with direct overlap in baking, brewing, animal nutrition, and human health probiotic categories.

TypeDirect peer
Description

Irish taste and nutrition company with bioscience-enabled ingredients for F&B; competes with Novonesis's food enzymes, cultures, and probiotic ingredient portfolio.

TypeBroad incumbent
Description

Global chemical major with a sizable industrial enzymes and biosolutions business serving feed, food, and industrial biotech; broader portfolio overlaps with Novonesis at the commodity end.

TypeBroad incumbent
Description

Global agribusiness and nutrition company with bioscience-enabled ingredients, animal nutrition, and fermentation capabilities that overlap with Novonesis's animal and plant biosolutions segment.

TypeBroad incumbent
Description

Privately held agribusiness giant with animal nutrition, food ingredients, and bioindustrial operations; competes in animal feed enzymes and food applications alongside Novonesis.

TypeEmerging player
Description

US-based protein engineering company developing novel enzymes and biocatalysts for pharmaceuticals and sustainable manufacturing; smaller but technologically adjacent to Novonesis's enzyme innovation pipeline.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature11 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries11 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Novonesis

Industrial Biotechnology and Biosolutionsnovonesis.com

Novonesis is a publicly traded Danish biosolutions company developing enzymes, microbes, probiotics, cultures, yeasts, and functional proteins for food and beverages, human health, household care, animal nutrition, bioenergy, and industrial bioprocessing customers across more than 30 industries globally.

What Novonesis does

Novonesis is a publicly traded biosolutions company headquartered in Hørsholm, Denmark (with principal operating presence at Lyngby), formed in January 2024 through the combination of Novozymes (spun off from Novo Nordisk in 2000) and Chr. Hansen (founded 1874). The company develops and sells enzyme, microbial, probiotic, culture, yeast, and functional protein biosolutions derived from biological sources for industrial and consumer applications. Its products span bioenergy (ethanol, biodiesel, biogas, renewable diesel, carbon capture), food and beverages (dairy, baking, beverages, meat, plant-based foods), household care (laundry and dishwash), human health (probiotics, early life nutrition, precision proteins), animal and plant solutions, and industrial bioprocessing (starch, oils & fats, leather, pulp & paper, sustainable plastics, textile, water treatment), with flagship trademarked platforms including Eversa, FlexFit, Cellic, Cellerity, Quara, BB-12, Pylopass, Urex, Alflorex, and DVS.

The technology stack rests on proprietary strain libraries and fermentation/biocatalysis platforms built over more than 100 years, paired with application engineering, regulatory dossier infrastructure for health claims, and approximately 25+ manufacturing facilities and R&D centers across the Americas, EMEA, and Asia Pacific. Strategic product franchises include proprietary probiotic strains documented over decades, enzymatic biodiesel processing (Eversa Advance, FlexFit), cellulosic ethanol enzyme blends (Cellic) and yeast (Cellerity), renewable diesel pretreatment (Quara LowP/Supreme), and emerging enzymatic carbon capture via carbonic anhydrase.

Novonesis generates revenue primarily through direct B2B product sales of biosolutions to enterprise customers across Food & Beverages, Human Health, and Planetary Health divisions, complemented by channel partnerships (notably Rovensa Next for US agricultural biosolutions) and regional distributors in emerging markets. The company serves more than 30 industries with 11,000+ employees and reports serving 200+ oils-and-fats plants globally; its biosolutions are embedded in 50%+ of all bread, yogurt, and cheese produced globally and reach 2 billion people daily through food applications. Leadership is anchored by a globally experienced executive team including CEO Ester Baiget (ex-Dow) and CFO Rainer Lehmann (ex-Sartorius), with Novo Holdings A/S (Novo Nordisk Foundation) controlling 25.50% of shares and 63.35% of voting rights via dual-class share structure. Q1 2026 results showed 7% organic sales growth and 37.8% adjusted EBITDA margin, supporting a 2026 revenue forecast of approximately $5.25 billion and a 2030 roadmap targeting 6-9% organic sales CAGR and ~39% adjusted EBITDA margin against a stated EUR 60 billion biosolutions TAM.

Novonesis firmographics

Firmographics
Name
Novonesis
Legal name
Novozymes A/S, part of Novonesis Group
Website
https://novonesis.com
Company type
Public
Founded year
2024
Operating status
Operating
Headcount range
5,001–10,000 employees
Short description
Novonesis is a publicly traded Danish biosolutions company developing enzymes, microbes, probiotics, cultures, yeasts, and functional proteins for food and beverages, human health, household care, animal nutrition, bioenergy, and industrial bioprocessing customers across more than 30 industries globally.
Ownership category
akta.pro rank

Novonesis industry classification

Industry
Product category
Industrial Biotechnology and Biosolutions
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833), Food And Kindred Products (2000)
akta.pro primary industry
Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling) (HLAAAJAF)

Keywords

  • Industrial enzyme solutions
  • Microbial biosolutions
  • Probiotic cultures
  • Bioenergy enzymes
  • Food fermentation ingredients

Where Novonesis is headquartered

Location

Headquarters

HQ city
Lyngby
HQ country
Denmark
HQ region
Europe

Offices26 records

Markets served

Novonesis business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Biosolutions Product Sales: Novonesis generates revenue primarily through the sale of biosolutions including enzymes, microbes, probiotics, cultures, yeasts, and functional proteins to customers across 30+ industries. Revenue is generated from product sales across Food & Beverages, Human Health, and Planetary Health divisions.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Novonesis product offering

Product offering

Core offering

Novonesis develops, manufactures, and sells biosolutions — enzymes, microbes, probiotics, cultures, yeasts, and functional proteins — to industrial customers across more than 30 industries. Its products are organized into two divisions: Planetary Health Biosolutions (food & beverages, bioenergy, household care, animal & plant, industrial bioprocessing) and Human Health Biosolutions (dietary supplements, early life nutrition, precision proteins). Revenue is generated primarily through direct product sales to enterprise customers supplemented by channel partner distribution.

Product overview

Novonesis is a world-leading biosolutions company offering a broad portfolio of enzyme, microbial, probiotic, culture, and functional protein products organized around two divisions: Planetary Health Biosolutions and Human Health Biosolutions. The company serves more than 30 industries including bioenergy (ethanol, biodiesel, biogas, biomass, renewable diesel, carbon capture), food and beverages (dairy, baking, beverages, meat, plant-based foods, functional foods), household care (laundry, dishwashing, home cleaning, industrial cleaning), human health (dietary supplements, early life nutrition, precision proteins, probiotics), and industrial bioprocessing (starch, oils & fats, leather, pulp & paper, sustainable plastics, textile, water treatment). The portfolio was significantly expanded through the January 2024 merger of Novozymes and Chr. Hansen, and further through the 2025 acquisition of dsm-firmenich's Feed Enzyme Alliance. Key product brands include Eversa® (biodiesel biocatalysts), FlexFit® (enzymatic process), Cellic® (biomass enzymes), Cellerity® (yeast technology), Quara® (oil processing), BB-12™ and Alflorex® (probiotics), Pylopass™ and Urex™ (microbiome strains), DVS® (fermentation technology), and the Protective Cultures platform for bioprotection. The company operates globally through approximately 100 subsidiaries and a direct commercial presence across all major regions.

Differentiator

Problem solved

Functional benefit

Brands

  • Eversa: Enzymatic biodiesel processing solutions including Eversa Advance and Eversa Transform 2.0 biocatalysts
  • FlexFit
  • Quara
  • Cellic
  • Cellerity
  • BB-12
  • Pylopass
  • Urex
  • PrecisionBiotics
  • DVS

Products and services

  • Eversa® Advance An enzymatic biocatalyst for biodiesel processing that enables conversion of used cooking oil and tallow into biodiesel, delivering up to 3% additional yield versus acid esterification and glycerolysis, and up to 45% reduction in operating costs. Targeted at biodiesel producers seeking feedstock flexibility.
  • Eversa® Transform 2.0 An enzyme biocatalyst that simultaneously catalyzes transesterification of glycerides and esterification of free fatty acids (FFA), enabling processing of low-quality feedstocks with high FFA content in biodiesel production. For biodiesel producers working with challenging feedstocks.
  • FlexFit® Biodiesel Process An enzymatic transesterification process for biodiesel production providing feedstock flexibility, reduced capital expenditure by avoiding expensive high-temperature equipment, and lower operating expenses through operation at 35–40°C. For biodiesel producers seeking capex and opex reductions.
  • Cellic® CTec3 HS A multi-enzyme blend for cellulosic ethanol production offering low cost-in-use and process flexibility, suited to simultaneous saccharification and fermentation (SSF) processes. For cellulosic ethanol producers converting agricultural residues.
  • Cellerity® 1.0 A yeast technology for cellulosic ethanol fermentation offering broad robustness, fast ethanol production, flexibility in nitrogen sources, lower CAPEX, and rapid xylose conversion. For second-generation biofuel producers.
  • Carbonic Anhydrase Enzymatic Carbon Capture An enzyme for post-combustion carbon capture that converts CO₂ molecules into carbonate, enabling more efficient and affordable capture compared to traditional chemical methods and requiring only 80°C thermal energy versus 120°C for conventional processes. For carbon capture, utilization, and storage (CCUS) operators.
  • Quara® LowP An enzymatic pretreatment solution for HVO/HEFA renewable diesel feedstocks that helps crushing and refining plants meet quality specifications with maximum yield and minimum by-products, providing feedstock flexibility and reducing waste. For renewable diesel producers.
  • Quara® Supreme A thermostable enzymatic water-degumming solution that improves crude vegetable oil yield and operational flexibility for soybean, rapeseed, and canola refining, reducing yield losses without increasing free fatty acids. For edible oil refiners.
  • HMO (Human Milk Oligosaccharides) Ingredients for early life nutrition that help infant formula provide nourishment closer to nature's intent. Production supported by the acquired Thailand facility from Meihua. For infant formula and early-life nutrition manufacturers.
  • Precision Proteins Tailored protein solutions to meet exact nutritional needs throughout consumers' different stages of life, part of the human health biosolutions portfolio. For human nutrition and dietary supplement manufacturers.
  • Microbial Solutions (Plant) Naturally occurring microbes and enzymes for agriculture that help farmers improve plant health and increase crop yield, supporting sustainable farming through biological interventions. For row crop, specialty crop, and forage producers, distributed in the US via Rovensa Next from the 2027 growing season.
  • Microbial Solutions (Animal) Science-based probiotics, microbes, and enzymes for animal health that work in synergy with agricultural strategies to drive consistent results in livestock production. For animal feed manufacturers and livestock producers, expanded through the dsm-firmenich Feed Enzyme Alliance acquisition completed in February 2025.
  • Laundry Enzymes Enzyme solutions for laundry applications that deliver superior cleaning at competitive price points, enabling biodegradable and renewable formulations. For detergent and household-care manufacturers.
  • Dishwashing Enzymes Enzyme solutions for dishwashing that boost performance from scrubbing power to quick cleaning, supporting eco-friendly, biodegradable, and renewable formulations. For automatic dishwashing detergent manufacturers.
  • DVS® Technology (Direct Vat Set) A fermentation technology introduced in 1978 that transformed fermentation into a modern biotechnology platform, enabling consistent, high-performance cultures for dairy and food fermentation. For dairy manufacturers producing cheese, yogurt, and other fermented dairy products.
  • Protective Cultures (Bioprotection) Food safety biosolutions launched in 2012 that slow spoilage yeasts and molds, keeping dairy products fresh for longer and reducing food waste. For dairy and food manufacturers seeking shelf-life extension.
  • Starch Enzymes Enzymes central to efficient starch processing, from corn separation to natural sweeteners, part of Novonesis's industrial bioprocessing portfolio. For starch processors and sweetener manufacturers.
  • Oils & Fats Enzymes Enzymatic processing solutions for oils and fats that reduce chemical use, enable switching to low-cost feedstocks, and improve profitability for edible oil producers. Used by 200+ oils and fats processing plants globally.
  • Leather Enzymes Biosolutions for leather processing that serve as alternatives to chemicals, making leather processing gentler and easier while significantly improving quality. For tanneries and leather goods manufacturers.
  • Pulp & Paper Enzymes Biosolutions for pulp and paper mills that help meet growing demand while achieving sustainability goals, reducing environmental impact of paper production. For pulp and paper manufacturers.
  • Sustainable Plastics Enzymes Enzymatic biosolutions that reduce the environmental impact of plastics and increase recyclability, addressing plastic waste through biological degradation. For plastics manufacturers and recyclers.
  • Textile Enzymes Biodegradable, environmentally friendly enzymes for textiles that support mills and laundries in the circular fashion movement. For textile mills and garment manufacturers.
  • Water Treatment Enzymes Enzyme solutions that improve water purification and process water quality while reducing chemical use, supporting efficient water recycling and lower environmental footprint. For water treatment and industrial process water operators.
  • Biogas Enzymes Tailor-made enzyme solutions for biogas production from agricultural residues, food production waste, wastewater, and sewage, delivering higher biogas yields, reduced operational costs, and prevention of hard crust formation in digesters. For biogas plant operators.
  • BB-12™ Probiotic Strain One of the world's most researched Bifidobacterium strains, supporting immune function, digestive health, and overall wellbeing across all ages, introduced in 1984. For dietary supplement, dairy, and infant nutrition manufacturers seeking clinically documented probiotic strains.
  • Feed Enzyme Alliance (Animal Nutrition) Animal feed enzyme business acquired from dsm-firmenich for approximately EUR 1.5 billion in February 2025, combining enzyme, microbe, and probiotic innovation for animal nutrition with global sales and distribution. For animal feed manufacturers and livestock producers.

Quantifiable outcome

  • 7% organic sales growth in Q1 2026
  • +7 more outcomes

Companies that use Novonesis

Customer profile

Named customers5 records

Segments1 record

Ideal customer profiles5 records

Novonesis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature11 records

Novonesis partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core, strategic, minor, innovation, acquisition and workforce development.

  • Nhà Xanh Vietnam (Nha Xanh)coreStrategic or Co-development Partner · 19 June 2026MoU signed at Embassy of Denmark in Hanoi to jointly boost domestic bioethanol production supporting Vietnam's E10 fuel rollout. Partnership combines Novonesis enzyme and yeast technology for corn and cassava-based ethanol with Nhà Xanh production infrastructure to address Vietnam's estimated 75,000 cubic meters monthly ethanol supply shortfall worth approximately USD 1 billion annually in imports.
  • Rovensa NextcoreChannel Partner/ Reseller/ Distributor · 11 June 2026Distribution agreement under which Rovensa Next commercializes select Novonesis agricultural biosolutions in the United States beginning with 2027 growing season. Rovensa Next assumes direct commercial responsibility for products covering soybeans, corn, pulses, peanuts, and fruit/vegetable crops, expanding its full crop-cycle portfolio from planting to post-harvest.
  • UndoAgestrategicStrategic or Co-development Partner · 9 June 2026MoU signed in Beijing forming strategic partnership to collaborate in China's probiotics and microbiome health market, focusing on stomach health and women's microbiome health segments. Collaboration leverages Novonesis proprietary probiotic strains (Pylopass™ and Urex™) and UndoAge consumer market expertise to develop science-backed products under 'Healthy China' strategy.
  • Rinck AdvertisingminorGTM or Marketing Partner · 21 May 2026Partnership earned 2026 PRSA Silver Anvil Award for Manufacturing Day 2025 campaign designed to inspire students about biomanufacturing careers. Novonesis was national flagship host site welcoming hundreds of students to facilities in North Carolina, Virginia, and Wisconsin.
  • BiocodexcoreStrategic or Co-development Partner · 23 April 2026Next phase of nine-year strategic partnership formalized with new agreement at leadership meeting in Copenhagen. Partnership focused on microbiome science and consumer health, expanding scientific collaboration and market reach for flagship product Alflorex®, now available in over 15 countries. Agreement expected to accelerate growth through deeper scientific collaboration.
  • KvantifyinnovationTechnology or Integration · 19 November 2025Danish quantum computing software company launched Qrunch platform for chemical and biological engineering industries. Novonesis already using technology to improve enzyme products and model larger molecular systems for pharmaceutical applications. Platform enables domain scientists to build quantum algorithms without quantum expertise.
  • thyssenkrupp UhdestrategicStrategic or Co-development Partner · 18 November 2025Partnership to develop enzymatic fat-splitting process replacing traditional thermal methods, reducing energy and water consumption in oleochemical production. New process operates at lower temperatures and pressures, offering significant cost savings, flexibility, and sustainability benefits.
  • SAIPEMstrategicStrategic or Co-development PartnerPartnership to deliver enzyme-based, cost-effective carbon capture solution. SAIPEM leverages expertise as leading EPC provider with advanced CCUS technology and proven track record in plant construction. Novonesis supports with robust global enzyme supply chain, R&D capabilities, and world-class enzyme quality for large-scale applications.
  • DTU (Technical University of Denmark)innovationStrategic or Co-development PartnerCollaboration on CO₂ to protein sustainable food innovation projects. Partnership leverages academic research capabilities with Novonesis industrial biotech expertise.
  • MeihuaacquisitionOthersNovonesis acquired production facility in Rayong, Thailand from Meihua for approximately USD 50 million, expanding footprint in Southeast Asia and strengthening fermentation capabilities. Facility expected to be commercially operational in 2027 and will support HMO production.
  • NC State Universityworkforce developmentOthersNovonesis supported development of NC State's agricultural formulations certificate program designed to prepare workforce-ready scientists for developing pesticides, fertilizers, growth regulators and biological products. Faculty from multiple departments collaborating on initiative.

Scale indicators28 records

Recent moves6 records

Expansion highlights7 records

Novonesis competitors and assessment

Company assessment

Direct peers

  • AB Enzymes (ABF Ingredients): Germany-based industrial enzyme specialist focused on food, beverage, and industrial applications; competes in baking, starch, and beverage enzyme categories.
  • International Flavors & Fragrances (IFF): IFF's Health & Biosciences division (including the legacy DuPont N&B enzyme and cultures business) directly competes with Novonesis in food enzymes, cultures, probiotics, and bioprocessing ingredients, serving overlapping F&B customers globally.
  • DSM-Firmenich: Dutch-Swiss nutrition and biosciences major; Novonesis acquired its Feed Enzymes Alliance in Feb 2025 but DSM-Firmenich remains a peer across animal nutrition, human nutrition, and personal care biosolutions.
  • Lesaffre: French global yeast and fermentation leader with overlapping capabilities in baking, brewing, bioethanol, and human nutrition probiotics; competes with Novonesis's DVS® cultures, yeast, and Cellerity® technologies.
  • Lallemand: Canadian privately held yeast and bacteria producer with direct overlap in baking, brewing, animal nutrition, and human health probiotic categories.
  • Kerry Group: Irish taste and nutrition company with bioscience-enabled ingredients for F&B; competes with Novonesis's food enzymes, cultures, and probiotic ingredient portfolio.

Broad incumbents

  • BASF: Global chemical major with a sizable industrial enzymes and biosolutions business serving feed, food, and industrial biotech; broader portfolio overlaps with Novonesis at the commodity end.
  • ADM (Archer Daniels Midland): Global agribusiness and nutrition company with bioscience-enabled ingredients, animal nutrition, and fermentation capabilities that overlap with Novonesis's animal and plant biosolutions segment.
  • Cargill: Privately held agribusiness giant with animal nutrition, food ingredients, and bioindustrial operations; competes in animal feed enzymes and food applications alongside Novonesis.

Emerging players

  • Codexis: US-based protein engineering company developing novel enzymes and biocatalysts for pharmaceuticals and sustainable manufacturing; smaller but technologically adjacent to Novonesis's enzyme innovation pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Novonesis social profiles

Digital presence

Novonesis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Novonesis leadership team

Management profile

Number of profiles

Profiles16 records

Novonesis subsidiaries and ownership

Company hierarchy

Subsidiaries11 records

Novonesis funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Novonesis M&A and investment

M&A and investment

M&A3 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novonesis

What does Novonesis do?

Novonesis develops, manufactures, and sells biosolutions — enzymes, microbes, probiotics, cultures, yeasts, and functional proteins — to industrial customers across more than 30 industries. Its products are organized into two divisions: Planetary Health Biosolutions (food & beverages, bioenergy, household care, animal & plant, industrial bioprocessing) and Human Health Biosolutions (dietary supplements, early life nutrition, precision proteins). Revenue is generated primarily through direct product sales to enterprise customers supplemented by channel partner distribution.

Is Novonesis a public or private company?

Novonesis is a public company. It is classified as public and is currently operating.

When was Novonesis founded?

Novonesis was founded in 2024. It employs 5,001 to 10,000 people.

Where is Novonesis based?

Novonesis is headquartered in Lyngby, Denmark, in the Europe region.

How does Novonesis make money?

One revenue line is on record: biosolutions Product Sales.

Who are Novonesis's main competitors?

Direct peers on record are AB Enzymes (ABF Ingredients), International Flavors & Fragrances (IFF), DSM-Firmenich, Lesaffre, Lallemand and Kerry Group. Broad incumbents are BASF, ADM (Archer Daniels Midland) and Cargill. Codexis is listed as an emerging player.

Does Novonesis have an API?

No public API is recorded for Novonesis.

What industry is Novonesis in?

Novonesis's product category is Industrial Biotechnology and Biosolutions. Its primary akta.pro industry code is HLAAAJAF, Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Simply Wall StHow Investors Are Reacting To Novonesis Stock As US Dairy Capacity ExpandsNovonesis completed a major expansion of its West Allis, Wisconsin facility, lifting North American dairy culture fermentation capacity by about 66% and packaging capacity by 17%. The project introduces automation-ready infrastructure and energy-efficient equipment, reshaping its cost base and environmental footprint. The expansion aligns with existing demand, but execution risks remain.WikipediaDraft:NovonesisNovonesis, a Danish biotechnology company, was formed in 2024 through the merger of Novozymes and Chr. Hansen. The merger, announced in December 2022, was the largest between two Danish companies, combining industrial enzymes with microbial cultures and food ingredients. The company is publicly traded on Nasdaq Copenhagen and has over 11,000 employees as of 2025.B2B MarketplaceDenmark's Novonesis completes acquisition of Australia's MicroBioGenNovonesis completed its acquisition of Australian biotechnology company MicroBioGen after receiving all regulatory approvals. The deal builds on Novonesis' 2013 investment and existing 23% stake, deepening a collaboration spanning over a decade. Novonesis says MicroBioGen's yeast-breeding expertise can support biosolutions beyond bioethanol across multiple industries.EuropaWireNovonesis brings MicroBioGen into group to expand industrial yeast and biosolutions expertiseNovonesis completed its acquisition of Australian biotech MicroBioGen after receiving all regulatory approvals. The deal builds on a 2013 investment and existing 23% stake, adding yeast-breeding expertise for bioethanol and other biosolutions. Novonesis will continue supporting MicroBioGen's existing partners.vegconomistNovonesis Takes Full Ownership of MicroBioGen as Yeast Deal Clears RegulatorsNovonesis completed its acquisition of MicroBioGen, a Sydney-based yeast strain developer, after obtaining all regulatory approvals. The deal closed seven weeks after signing, with Novonesis previously holding a 23% stake. The company plans to apply MicroBioGen's yeast technology beyond bioethanol, including in feed and food applications.FinancialContent Business PageNovonesis completes acquisition of MicroBioGen, strengthening its yeast capabilitiesNovonesis completed its acquisition of MicroBioGen, an Australian biotechnology firm specializing in yeast strains for industrial applications. The deal, which closed after regulatory approvals, builds on Novonesis' 2013 investment and existing 23% stake. The acquisition strengthens Novonesis' yeast and R&D capabilities for bioethanol and other industries.FinancialContent Business PageNovonesis celebrates major expansion of West Allis production facility, strengthening North American dairy innovation and manufacturingNovonesis completed a major expansion at its West Allis, Wisconsin production facility, increasing North American dairy culture production capacity by about 66% and packaging capacity by 17%. The expansion establishes the site as one of the world's largest lactobacillus production facilities and adds new jobs.Investing.comStock Market News - Investing.com IndiaJPMorgan kept a cautious view on European chemicals, citing structural overcapacity and rising competition from China and other emerging-market producers. The bank's 2027 earnings estimates sit materially below consensus for much of the sector, with Novonesis as its top long and BASF, Wacker, and others rated Underweight.PR NewswireEnzymes Market worth $23.74 billion by 2031- Exclusive Report by MarketsandMarkets™MarketsandMarkets projects the global enzymes market to grow from $16.15 billion in 2026 to $23.74 billion by 2031, an 8.0% CAGR. Growth is driven by adoption in food & beverages, biofuels, and wastewater treatment, with industrial enzymes expected to hold the largest share.Mirage NewsClinTec, Partners Develop New Protein for Critical CareResearchers at Karolinska Institutet and food companies Arla Foods Ingredients and Novonesis are developing a nutritional protein to support patients in acute catabolic conditions. The project, funded with SEK 6.3 million, combines clinical studies with in vitro screening using human liver and muscle cells.